Expertise in
1
conditions

Dr. Andrew Wagner

Emergency Medicine
STAT Doctors Medical Group LTD.
4535 Dressler Rd NW, 
Canton, OH 
Expertise in
1
conditions
STAT Doctors Medical Group LTD.
4535 Dressler Rd NW, 
Canton, OH 

Overview

Andrew Wagner is an Emergency Medicine provider in Canton, Ohio. Dr. Wagner is highly rated in 1 condition, according to our data. His top areas of expertise are Non-Muscle Invasive Bladder Cancer, Tissue Biopsy, and Prostatectomy.

His clinical research consists of co-authoring 147 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Emergency Medicine

Licenses

Emergency Medicine in OH

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Friday Health

Accepted plan types not found. Please verify directly with the provider.

Managed Medicaid
  • OTHER MANAGED MEDICAID

Locations

STAT Doctors Medical Group LTD.
4535 Dressler Rd NW, Canton, OH 44718
Other Locations
Mercy Hospital
1010 Three Springs Blvd, Durango, CO 81301

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma
A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma
Enrollment Status: Active_not_recruiting
Publish Date: January 09, 2026
Intervention Type: Drug
Study Drug: INBRX-109
Study Phase: Phase 2
An Open-Label, Multicenter, Phase 1a/1b Study of Olaratumab (LY3012207) Plus Pembrolizumab (MK3475) in Patients With Unresectable Locally Advanced or Metastatic Soft Tissue Sarcoma (STS) Who Have Failed Standard Treatments
An Open-Label, Multicenter, Phase 1a/1b Study of Olaratumab (LY3012207) Plus Pembrolizumab (MK3475) in Patients With Unresectable Locally Advanced or Metastatic Soft Tissue Sarcoma (STS) Who Have Failed Standard Treatments
Enrollment Status: Completed
Publish Date: October 23, 2024
Intervention Type: Drug
Study Drugs: Olaratumab, Pembrolizumab
Study Phase: Phase 1
A Phase 1, First-in-human, Open-label, Dose Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-1287 to Patients with Advanced Solid Tumors
A Phase 1, First-in-human, Open-label, Dose Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-1287 to Patients with Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: September 19, 2024
Intervention Type: Drug
Study Drug: TP-1287
Study Phase: Phase 1
A Phase 1 Open-Label, Dose-Finding Study Evaluating Safety and Pharmacokinetics of FPA144 in Patients With Advanced Solid Tumors
A Phase 1 Open-Label, Dose-Finding Study Evaluating Safety and Pharmacokinetics of FPA144 in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: June 04, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Phase 2-3, Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (DDLS)
A Phase 2-3, Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (DDLS)
Enrollment Status: Completed
Publish Date: January 23, 2023
Intervention Type: Drug
Study Drug: Selinexor
Study Phase: Phase 2/Phase 3
A Phase 1b (Open-Label)/Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma
A Phase 1b (Open-Label)/Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma
Enrollment Status: Completed
Publish Date: May 09, 2022
Intervention Type: Drug
Study Drugs: Olaratumab, Gemcitabine, Docetaxel
Study Phase: Phase 1/Phase 2
A Phase 1/2 Study of Cabiralizumab, an Anti-CSF1 Receptor Antibody, in Patients With Pigmented Villonodular Synovitis (PVNS)/ Diffuse Type Tenosynovial Giant Cell Tumor (Dt-TGCT)
A Phase 1/2 Study of Cabiralizumab, an Anti-CSF1 Receptor Antibody, in Patients With Pigmented Villonodular Synovitis (PVNS)/ Diffuse Type Tenosynovial Giant Cell Tumor (Dt-TGCT)
Enrollment Status: Completed
Publish Date: August 31, 2021
Intervention Type: Biological
Study Phase: Phase 1/Phase 2
A Phase Ib/II Study of BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)
A Phase Ib/II Study of BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)
Enrollment Status: Completed
Publish Date: March 30, 2020
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1, Open-label, Dose-escalation and Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CDX-0158 in Adult Patients With KIT Positive Advanced Solid Tumors.
A Phase 1, Open-label, Dose-escalation and Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CDX-0158 in Adult Patients With KIT Positive Advanced Solid Tumors.
Enrollment Status: Completed
Publish Date: June 12, 2019
Intervention Type: Biological
Study Phase: Phase 1
View 8 Less Clinical Trials

147 Total Publications

A plain language summary of the AMPECT study: nab-sirolimus for advanced malignant perivascular epithelioid cell tumors.
A plain language summary of the AMPECT study: nab-sirolimus for advanced malignant perivascular epithelioid cell tumors.
Journal: Future oncology (London, England)
Published: December 22, 2025
Similar Doctors
Expertise in
1
conditions
Dr. Kevin P. Collins
Emergency Medicine
Expertise in
1
conditions
Dr. Kevin P. Collins
Emergency Medicine

US Acute Care Solutions

4535 Dressler Rd NW, 
Canton, OH 
 (1432.4 miles away)
631-503-3395
Experience:
15+ years
Languages Spoken:
English
See accepted insurances

Kevin Collins is an Emergency Medicine provider in Canton, Ohio. Dr. Collins has been practicing medicine for over 15 years is highly rated in 1 condition, according to our data. His top areas of expertise are Schizoaffective Disorder and Inappropriate Sinus Tachycardia (IST).

Expertise in
16
conditions
Dr. Andrew Filiatraut
Emergency Medicine
Expertise in
16
conditions
Dr. Andrew Filiatraut
Emergency Medicine

Office

2535 Hale St Ste A, 
Avon, OH 
 (1404.5 miles away)
440-827-5195
Languages Spoken:
English
See accepted insurances

Andrew Filiatraut is a primary care provider, practicing in Emergency Medicine in Avon, Ohio. Dr. Filiatraut is highly rated in 16 conditions, according to our data. His top areas of expertise are Infant Hyperglycemia, Lung Metastases, Glucocorticoid-Remediable Aldosteronism, Pacemaker Implantation, and Ureteroscopy.

Expertise in
3
conditions
Dr. Timothy Genetta
Emergency Medicine
Expertise in
3
conditions
Dr. Timothy Genetta
Emergency Medicine

Weirton Medical Center

601 Colliers Way, 
Weirton, WV 
 (1479.7 miles away)
304-797-6100
Languages Spoken:
English
See accepted insurances

Timothy Genetta is an Emergency Medicine provider in Weirton, West Virginia. Dr. Genetta is highly rated in 3 conditions, according to our data. His top areas of expertise are Boils, Folliculitis, and Carbuncle.

Frequently Asked Questions about Dr. Andrew Wagner

How do I make an appointment with Dr. Andrew Wagner?

You can book an appointment with Dr. Andrew Wagner by calling their office at 330-493-4443. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Andrew Wagner a top-rated expert for Tissue Biopsy?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Andrew Wagner is classified as an Advanced expert for Tissue Biopsy, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Andrew Wagner specialize in?

While Dr. Andrew Wagner is a Emergency Medicine, they have specific expertise in Tissue Biopsy, Non-Muscle Invasive Bladder Cancer, and Prostatectomy. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Emergency Medicine.

Does Dr. Andrew Wagner participate in research or clinical trials?

Yes. Dr. Andrew Wagner has published 147 articles and abstracts on conditions like Tissue Biopsy. You can view a list of Dr. Andrew Wagner's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Andrew Wagner accept my insurance?

Dr. Andrew Wagner accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 330-493-4443 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Wagner's expertise for a condition
ConditionClose
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile